My watch list  

10 Current news of abbvie


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
AbbVie Acquires Syndesi Therapeutics

Strengthening Neuroscience Portfolio


AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. ...


Major pharma companies sign up to groundbreaking Parkinson's consortium


Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's. The Critical Path for Parkinson's consortium will bring together leading academics; industry members AbbVie, ...


Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Meets Primary Endpoint


AbbVie announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achievingoverall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review ...


AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis


AbbVie announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. Patients received 12 weeks of VIEKIRAX® ...


AbbVie Completes Acquisition of Pharmacyclics


AbbVie announced that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a company in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ...


AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy


AbbVie announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to ...


AbbVie to Acquire Pharmacyclic


AbbVie and Pharmacyclics announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies. The acquisition accelerates AbbVie's clinical and commercial presence in oncology, ...


European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA


AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for ...


AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland

€85 million investment creates greater manufacturing capacity to deliver new medicines for patients


The Chairman and CEO of AbbVie Inc. Richard A. Gonzalez officially opened the company's newly expanded facility in Sligo, Ireland. The site is a strategic asset for AbbVie due to its involvement in the commercialization and manufacturing of AbbVie pipeline products in liver disease, oncology and ...


AbbVie Announces Michael Severino, M.D. to Lead R&D Organization


AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE